Market Overview

Wunderlich Securities Sees Traffic Data Tracking Well For MeetMe


In a report published Thursday, Wunderlich Securities analyst Blake T. Harper reiterated a Buy rating and $4.50 price target on MeetMe Inc (NASDAQ: MEET).

In the report, Wunderlich Securities noted, “MeetMe, Inc. (MEET) traffic data from Quantcast has been tracking well, with visitors up ~25% Y/Y for the months of October and November compared to our estimate for mobile daily active users (DAUs) to grow 23% Y/Y in Q4. Chinese social-mobile app Momo (MOMO-NR) is expected to begin trading today and the middle of its expected IPO pricing range represents a ~95x EV/S multiple on its expected 2014 sales compared 1.4x EV/S for MEET. While Momo is growing revenues and users substantially faster than MeetMe and is addressing a much larger mobile internet market in China, we believe the extreme disparity is unjustified for both. MeetMe also introduced a virtual currency product which should add an incremental revenue stream and the CFO bought 6k shares in the open market.”

MeetMe closed on Wednesday at $1.62.

Latest Ratings for MEET

Jun 2019Initiates Coverage OnOutperform
Jul 2018UpgradesHoldBuy
Nov 2017DowngradesMarket OutperformMarket Perform

View More Analyst Ratings for MEET
View the Latest Analyst Ratings

Posted-In: Blake T. Harper Wunderlich SecuritiesAnalyst Color Reiteration Analyst Ratings


Related Articles (MEET)

View Comments and Join the Discussion!

Latest Ratings

ADBECleveland ResearchInitiates Coverage On283.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: UBS Downgrades Travelers Companies, Cites Valuation 'Looks Full'

UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical On Path To Long-Term Upside